Register Login
Register to leave comments
  • News bot Jan. 29, 2026, 6:47 p.m.

    📋 AgeX Therapeutics Inc. (was merged with Biotechnology Serina Therapeutics (NYSE: SER) on 27/04/2024) (AGE) - Clinical Trial Update

    Filing Date: 2026-01-15

    Accepted: 2026-01-15 16:03:11

    Event Type: Clinical Trial Update

    Event Details:

    AgeX Therapeutics Inc. (was merged with Biotechnology Serina Therapeutics (NYSE: SER) on 27/04/2024) (AGE) Announces Clinical Trial Update AgeX Therapeutics Inc. (was merged with Biotechnology Serina Therapeutics (NYSE: SER) on 27/04/2024) (AGE) provided an update on its clinical development programs. Clinical Development Highlights:
    • Collaboration: SER
    • Updated Timeline: fiscal years ended December 31, 2024, September 30, 2025

    🔬 Clinical Development Pipeline (AgeX Therapeutics Inc. (was merged with Biotechnology Serina Therapeutics (NYSE: SER) on 27/04/2024)):

    Product Type Development Stage Therapeutic Area Source
    Placebo Gel OTHER Phase PHASE2 EGFR Inhibitor-Induced Skin Rash ClinicalTrials.gov
    AC-701 Topical Gel 0.3% DRUG Phase PHASE2 EGFR Inhibitor-Induced Skin Rash ClinicalTrials.gov
    Tofacitinib Citrate DRUG Phase PHASE1 Healthy Subjects ClinicalTrials.gov
    Febuxostat DRUG Phase PHASE2 Gout ClinicalTrials.gov
    AC-201 DRUG Phase PHASE2 Gout ClinicalTrials.gov
    Placebo DRUG Phase PHASE2 Gout ClinicalTrials.gov
    SER-214 DRUG Phase PHASE1 Parkinson's Disease ClinicalTrials.gov
    BRM421 Ophthalmic Solution, 0.06% DRUG Phase PHASE2 Dry Eye Disease (DED) ClinicalTrials.gov
    Vehicle Ophthalmic Solution DRUG Phase PHASE2 Dry Eye Disease (DED) ClinicalTrials.gov
    BRM421 Ophthalmic Solution, 0.03% DRUG Phase PHASE2 Dry Eye Disease (DED) ClinicalTrials.gov
    Vehicle DRUG Phase PHASE2 Generalized Epidermolysis Bullosa Simplex ClinicalTrials.gov
    AC-203 DRUG Phase PHASE2 Generalized Epidermolysis Bullosa Simplex ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AgeX Therapeutics Inc. (was merged with Biotechnology Serina Therapeutics (NYSE: SER) on 27/04/2024)
    • Ticker Symbol: AGE

Search

News categories